Back to top

Buy Rating Reaffirmed on Arcus Biosciences as New RCC Partnerships Strengthen Multi-Line Development Strategy

Citi analyst Yigal Nochomovitz maintained a Buy rating on Arcus Biosciences yesterday and set a price target of $45.00. Yigal Nochomovitz has given...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Arcus Biosciences, Inc. (RCUS)